Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorvotuzumab mertansine in relapsed SCLC and solid tumors
NCT00065429Phase 2Completed
- Sponsor
- ImmunoGen
- Start
- Apr 2003
- Primary completion
- Nov 2008
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of lorvotuzumab mertansine in small cell lung cancer (SCLC) and solid tumor (7 arms), sponsored by ImmunoGen. Primary endpoints: Phase I Toxicity Based Upon Adverse Events and Objective Response Rate at 6 weeks. Started Apr 2003; status: completed.
02
Drugs
lorvotuzumab mertansine
03
Conditions
small cell lung cancer (SCLC)solid tumor
Beyond the preview
Go deeper on NCT00065429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00065429.